Sienna Biopharmaceuticals Announces $40 Million Series B Financing

Sienna Biopharmaceuticals Announces $40 Million Series B Financing 

Topical Biotech Innovation in Medical Dermatology and Aesthetics

Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by existing investors ARCH Venture Partners and Venvest Capital.

Additional investors participating included Partner Fund Management, Altitude Life Science Ventures, and Dr. David Pyott. New investors accounted for approximately half of the investments and included Fidelity Management & Research Company, certain investment funds advised by Clough Capital Partners L.P, Omega Fund Management, and others. Sienna’s mission is to develop safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic problems that impact the health, appearance, and quality of life of patients.

Sienna intends to use the proceeds from this financing to advance its diversified topical biotech pipeline. Sienna is developing its lead assets, for pruritus and psoriasis (Phase IIb) and for atopic dermatitis, psoriasis and pruritus (proof-of-concept), for the treatment of acne vulgaris (pivotal trials) and for the permanent reduction of unwanted light-pigmented hair (pivotal trials).

Frederick C. Beddingfield III, MD, PhD, Sienna’s President and Chief Executive Officer said “We believe this financing will enable us to advance our development programs, which span pivotal clinical trials to preclinical programs.”

Find more information at www.siennabio.com.

Leave a Reply